TRPM2 and acute myeloid leukemia: Expression of TRPM2 in AML samples from patients with normal karyotypes and all major AML mutational subgroups including aberrant complex karyotypes was significantly greater than that measured in normal hematopoietic stem cells (HSC) or common myeloid progenitors (CMP) (Fig. 1b).